BioCentury
ARTICLE | Finance

Deerfield pays Tribute to Pozen

Why Deerfield is giving war chest to Pozen to buy Tribute and more

June 15, 2015 7:00 AM UTC

Deerfield is betting $300 million on the combination of a Canadian cardiovascular specialty pharma with a U.S. biotech that has new management, a late-stage cardio asset and a royalty stream.

The firm is backing a deal by Pozen Inc. (NASDAQ:POZN) to buy Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF; TSX-V:TRX) for $146 million...